Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 308Carcinoma, Non-Small-Cell Lung 241Prostatic Neoplasms 198Neoplasms 191Lung Neoplasms 149Multiple Myeloma 144Neoplasm Metastasis 110Colorectal Neoplasms 105Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 81Pancreatic Neoplasms 77Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 70Carcinoma, Renal Cell 68Lymphoma, Non-Hodgkin 64Squamous Cell Carcinoma of Head and Neck 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 59Urinary Bladder Neoplasms 58Recurrence 56Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Glioblastoma 53Endometrial Neoplasms 52Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Sarcoma 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 46

Interventions

Paracentesis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Malignant Ascites × 90 days × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡